Full Coverage

Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.

biowizard.com
May 19, 2008
        
Story Timeline:  197 days

Departments of Surgery, Pathology, Pharmacology and Cancer Biology, and Medicine, and Institute for Genome Sciences and Policy, Duke University. Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin, which is associated with increased motility and... [read full story]                    

Add Comment
Latest article on this story:

Therapy Packs One-Two Punch Against Melanoma

 emaxhealth.com May 20, 2008
First article on this story:

Adherex Announces ASCO Abstract of ADH-1 in Melanoma

 marketwire.com May 19, 2008
Selected publications with coverage of this story:
marketwire.com yahoo.com biowizard.com ivanhoe.com emaxhealth.com
RELATED
Found 5 documents:
                   

Therapy Packs One-Two Punch Against Melanoma

emaxhealth.com
May 20, 2008
        

Skin Cancer Symptoms and Treatment Disabling a protein frequently found in melanoma tumors may make the cancer more vulnerable to chemotherapy, according to a pilot study led by researchers in the Duke Comprehensive Cancer Center. "We tested a compound that can weaken the tumor by targeting a...

                   

New Treatment for Deadly Melanoma

ivanhoe.com
May 20, 2008
        

One of the deadliest and most highly diagnosed malignant melanomas is vulnerable to a combination of chemotherapy and a protein-disabling drug, according to a new study. Researchers at Duke University’s Comprehensive Cancer Center were able to reduce melanoma tumors in rats 30-fold by first...

                   

Adherex Announces ASCO Abstract of ADH-1 in Melanoma (Marketwire)

yahoo.com
May 19, 2008
        

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(MARKET WIRE)--May 19, 2008 -- Adherex Technologies Inc. (AMEX: ), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today the publication of an abstract on the phase I/II study of ADH-1 in combination with isolated...

                   

Adherex Announces ASCO Abstract of ADH-1 in Melanoma

marketwire.com
May 19, 2008
        

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - May 19, 2008) - Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today the publication of an abstract on the phase I/II study of ADH-1 in combination...

                   

Adherex Technologies Inc.: Adherex Announces ASCO Abstract of ADH-1 in Melanoma

marketwire.com
May 19, 2008
        

RESEARCH TRIANGLE PARK, NORTH CAROLINA (MARKET WIRE) Adherex Technologies Inc. (AMEX: ADH)(TSX: AHX), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today the publication of an abstract on the phase I/II study of ADH-1 in combination with isolated limb...